Integral Investment Advisors Inc. Sells 26,038 Shares of Pfizer Inc. (NYSE:PFE)

Integral Investment Advisors Inc. reduced its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 46.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,487 shares of the biopharmaceutical company's stock after selling 26,038 shares during the period. Integral Investment Advisors Inc.'s holdings in Pfizer were worth $747,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Rialto Wealth Management LLC bought a new position in Pfizer during the fourth quarter valued at about $26,000. Clarity Asset Management Inc. acquired a new position in Pfizer during the 4th quarter valued at $27,000. Gould Capital LLC raised its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer during the fourth quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer in the fourth quarter worth $30,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

PFE has been the subject of several recent research reports. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. UBS Group increased their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Trading Up 0.8%

Shares of PFE stock traded up $0.21 on Wednesday, hitting $24.51. The stock had a trading volume of 15,212,869 shares, compared to its average volume of 40,937,157. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a fifty day moving average price of $22.93 and a two-hundred day moving average price of $24.98. The firm has a market cap of $139.32 billion, a P/E ratio of 17.40, a PEG ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the firm posted $0.82 earnings per share. Pfizer's revenue was down 7.8% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.02%. Pfizer's dividend payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.